LT3436019T - (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trichlorfenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamidas ir jo naudojimo būdai - Google Patents

(1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trichlorfenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamidas ir jo naudojimo būdai

Info

Publication number
LT3436019T
LT3436019T LTEPPCT/US2017/025289T LTUS2017025289T LT3436019T LT 3436019 T LT3436019 T LT 3436019T LT US2017025289 T LTUS2017025289 T LT US2017025289T LT 3436019 T LT3436019 T LT 3436019T
Authority
LT
Lithuania
Prior art keywords
amino
fluorethetrahydro
purin
trichlorophenyl
pyran
Prior art date
Application number
LTEPPCT/US2017/025289T
Other languages
English (en)
Inventor
Zheng Chen
Paul Fernandez
Tracy GAEBELE
Lianfeng Huang
Matthew Jackson
Matthew KREILEIN
Xiaoling Lu
Wenju Wu
Jean Xu
Original Assignee
Signal Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals, Llc filed Critical Signal Pharmaceuticals, Llc
Publication of LT3436019T publication Critical patent/LT3436019T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2017/025289T 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trichlorfenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamidas ir jo naudojimo būdai LT3436019T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317468P 2016-04-01 2016-04-01
PCT/US2017/025289 WO2017173218A1 (en) 2016-04-01 2017-03-31 Solid forms of (1s,4s)-4-(2-(((3s4r)-3-fluorotetrahydro-2h-pyran-4-yl) amino)-8-((2,4,6-trichlorophenyl) amino)-9h-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use

Publications (1)

Publication Number Publication Date
LT3436019T true LT3436019T (lt) 2021-10-25

Family

ID=59960229

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/025289T LT3436019T (lt) 2016-04-01 2017-03-31 (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trichlorfenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamidas ir jo naudojimo būdai

Country Status (19)

Country Link
US (2) US10047090B2 (lt)
EP (2) EP3845536A1 (lt)
JP (1) JP6995058B2 (lt)
CN (1) CN109819649B (lt)
AU (1) AU2017240050B2 (lt)
CA (1) CA3019105A1 (lt)
CY (1) CY1124677T1 (lt)
DK (1) DK3436019T3 (lt)
ES (1) ES2895419T3 (lt)
HR (1) HRP20211546T1 (lt)
HU (1) HUE056631T2 (lt)
LT (1) LT3436019T (lt)
MX (1) MX379439B (lt)
PL (1) PL3436019T3 (lt)
PT (1) PT3436019T (lt)
RS (1) RS62496B1 (lt)
SI (1) SI3436019T1 (lt)
SM (1) SMT202100604T1 (lt)
WO (1) WO2017173218A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230035424A (ko) 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
SG11201808388QA (en) * 2016-04-01 2018-10-30 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
ES3032365T3 (en) * 2016-06-21 2025-07-17 Assia Chem Ind Ltd Solid state forms of ixazomib citrate
EP3691687A1 (en) 2017-10-04 2020-08-12 Celgene Corporation Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
EP3692041A1 (en) * 2017-10-04 2020-08-12 Celgene Corporation Processes for the preparation of cis-4 [2-{(3s.4r)-3-fluorooxan-4-yl]amino)-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
CR20210665A (es) 2019-05-21 2022-01-25 Amgen Inc Formas en estado sólido
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN116710475A (zh) * 2020-12-15 2023-09-05 国家科学研究中心 Sqstm1及其在癌症疗法中的用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
CN101360725B (zh) 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
NZ576347A (en) 2006-10-27 2011-10-28 Signal Pharm Llc Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith
DK2279731T3 (da) 2008-04-23 2013-03-18 Farmasierra Mfg S L Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein
US20130034495A1 (en) 2009-12-09 2013-02-07 Marie Georges Beauchamps Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
KR20230035424A (ko) * 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
SG11201808388QA (en) 2016-04-01 2018-10-30 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
CA3019105A1 (en) 2017-10-05
US10513519B2 (en) 2019-12-24
SMT202100604T1 (it) 2021-11-12
WO2017173218A1 (en) 2017-10-05
PT3436019T (pt) 2021-11-04
ES2895419T3 (es) 2022-02-21
SI3436019T1 (sl) 2021-12-31
US20180362529A1 (en) 2018-12-20
PL3436019T3 (pl) 2022-01-10
MX379439B (es) 2025-03-10
CY1124677T1 (el) 2022-07-22
MX2018011970A (es) 2019-05-20
RS62496B1 (sr) 2021-11-30
DK3436019T3 (da) 2021-10-11
EP3436019A4 (en) 2019-08-28
EP3845536A1 (en) 2021-07-07
EP3436019B1 (en) 2021-07-28
CN109819649A (zh) 2019-05-28
JP2019515889A (ja) 2019-06-13
AU2017240050A1 (en) 2018-10-11
US10047090B2 (en) 2018-08-14
US20170283418A1 (en) 2017-10-05
EP3436019A1 (en) 2019-02-06
JP6995058B2 (ja) 2022-02-21
HRP20211546T1 (hr) 2022-01-07
AU2017240050B2 (en) 2021-12-16
CN109819649B (zh) 2023-02-28
HUE056631T2 (hu) 2022-02-28

Similar Documents

Publication Publication Date Title
LT3436019T (lt) (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-trichlorfenil)amino)-9h-purin-9-il)-1-metilcikloheksan-1-karboksamidas ir jo naudojimo būdai
LT3706762T (lt) N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai
IL266611A (en) Converted N-(3-fluorophenyl)-pyrrolidine substances, process for their preparation and medical use thereof
EP3655432A4 (en) BINDING PROTEINS 1
LT3409259T (lt) Daugiakamerinis lankstus maišelis ir jo panaudojimo būdai
EP3509511A4 (en) WRIST ARCHITECTURE
HRP20251569T1 (hr) Mutanti proteina rsv f
LT3442947T (lt) Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai
EP3402519A4 (en) Multispecific immunomodulatory antigen-binding constructs
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
EP3500943A4 (en) FINGERPRINT LAYOUTS FOR FINGERPRINTING CONTENT
ZA202007547B (en) Heteroaryl compounds and uses thereof
MA46717A (fr) Variantes de l'endonucléase homing tcra
SG10201603913SA (en) Induced aperture lens and method
EP3291722A4 (en) IMPROVED LENS OPPORTER
DK3464331T3 (da) Stabiliserede præfusions-rsv f-proteiner
EP3514167A4 (en) THROMBOSPONDIN 1 BINDING PEPTIDE
DK3463351T3 (da) Behandling til parkinsons sygdom
EP3479270A4 (en) ANALYTICAL CARDS FOR REACTION TO INCIDENTS
LT3587420T (lt) Triciklis junginys ir jo naudojimas
EP3604281A4 (en) 2(1h)-quinolinone derivative
EP3511327A4 (en) TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF
LT3573611T (lt) Amidų junginiai ir jų naudojimas
DK3259255T3 (da) (2r,4r)-5-(5'-chlor-2'-fluorbiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazol-2-carbonyl)amino]pentansyre
KR102135648B9 (ko) 항독성 또는 항병원성 활성을 갖는 레오이딘 화합물 및 이의 용도